"Palivizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal antibody and ANTIVIRAL AGENT that is used to prevent RESPIRATORY SYNCYTIAL VIRUS INFECTIONS in high risk pediatric patients.
Descriptor ID |
D000069455
|
MeSH Number(s) |
D12.776.124.486.485.114.224.060.860 D12.776.124.790.651.114.224.060.860 D12.776.377.715.548.114.224.200.860
|
Concept/Terms |
MEDI 493- MEDI 493
- Monoclonal Antibody MEDI-493
- Monoclonal Antibody MEDI 493
- Monoclonal Antibody MEDI493
- MEDI-493
- MEDI493
|
Below are MeSH descriptors whose meaning is more general than "Palivizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Palivizumab [D12.776.124.486.485.114.224.060.860]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Palivizumab [D12.776.124.790.651.114.224.060.860]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Palivizumab [D12.776.377.715.548.114.224.200.860]
Below are MeSH descriptors whose meaning is more specific than "Palivizumab".
This graph shows the total number of publications written about "Palivizumab" by people in this website by year, and whether "Palivizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2017 | 5 | 3 | 8 |
2018 | 3 | 2 | 5 |
2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Palivizumab" by people in Profiles.
-
CHILDREN WITH CYSTIC FIBROSIS HOSPITALISED WITH COVID-19: MULTICENTRE EXPERIENCE. J Paediatr Child Health. 2021 05; 57(5):767-768.
-
Respiratory syncytial virus and palivizumab prophylaxis in the COVID-19 era. CMAJ. 2021 04 12; 193(15):E523.
-
Saudi experts' recommendation for RSV prophylaxis in the era of COVID-19: Consensus from the Saudi Pediatric Pulmonology Association. Saudi Med J. 2021 Apr; 42(4):355-362.
-
Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. Pediatrics. 2019 05; 143(5).
-
Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. Vaccine. 2018 12 18; 36(52):8069-8078.
-
Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches. Eur J Clin Microbiol Infect Dis. 2018 Oct; 37(10):1817-1827.
-
Severe outcomes associated with respiratory viruses in newborns and infants: a prospective viral surveillance study in Jordan. BMJ Open. 2018 05 20; 8(5):e021898.
-
Comparison of Palivizumab-Like Antibody Binding to Different Conformations of the RSV F Protein in RSV-Infected Adult Hematopoietic Cell Transplant Recipients. J Infect Dis. 2018 03 28; 217(8):1247-1256.
-
Safety of Palivizumab Stewardship in Conjunction with Infection Prevention and Control Strategies for Healthcare-Associated Respiratory Syncytial Virus Infections. Infect Control Hosp Epidemiol. 2018 04; 39(4):485-487.
-
Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein. Nat Commun. 2017 11 30; 8(1):1877.